| Old Articles: <Older 921-930 Newer> |
|---|
 |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument.   |
Bio-IT World
February 2006
Robert M. Frederickson |
Experiments in Data Integration Teranode evolved from a group of University of Washington scientists and has rapidly become a leading developer of informatics software for bio-scientists. |
Bio-IT World
February 2006 |
News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance... |
Bio-IT World
February 2006
Steven Withrow |
Northrop Grumman, UTSW Boost Biodefense Resources Fighting bioterrorism and infectious disease is not part of the usual IT job description. But Northrop Grumman's IT sector routinely moves beyond the usual, having garnered two multimillion-dollar bioinformatics development contracts since 2004. |
Bio-IT World
February 2006
Juan Carlos Perez |
Google, Venter Mum on Collaboration Reports Google and the J. Craig Venter Institute are playing down highly publicized reports of a genetics research collaboration reported in the recently published The Google Story by David Vise and Mark Malseed. |
Bio-IT World
February 2006 |
News Blast Franklin Award... Improved Sensitivity... Discovery Tag Team... NIH Screening Begins... |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
February 2006
John Russell |
Preventable Vioxx Problems? Pathway analysis tools might have identified Vioxx's problematic off-target activity much earlier. Wondering which modeling approach to use for your project? |
BusinessWeek
March 6, 2006
Bruce Einhorn |
A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy. |
Chemistry World
February 23, 2006
Henry Nicholls |
Mind-Altering Drugs at the Olympics As further evidence of performance-enhancing drug use at the Winter Olympics in Turin emerges, researchers have unveiled the first study to quantify the psychological effects of taking recombinant human erythropoietin (rHuEPO) on endurance athletes. |
| <Older 921-930 Newer> Return to current articles. |
